Edwards Lifesciences’ EW fourth-quarter performance was backed by its most comprehensive structural heart disease portfolio. The Surgical Structural Heart business is benefiting from the strong ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback